ELTX · Elicio Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.76M | - | $5.04M | $7.01M | $7.78M | - | $7.21M | $8.18M | $7.56M | - |
| SG&A | $3.85M | - | $3.01M | $3.08M | $2.96M | - | $3.14M | $2.74M | $2.68M | - |
| Total Operating Expenses | $10.60M | - | $8.04M | $10.09M | $10.74M | - | $10.34M | $10.92M | $10.24M | - |
| D&A | $46.0K | - | $100.0K | $100.0K | $53.0K | - | $0 | - | $82.0K | - |
| Operating Income | ($10.60M) | - | ($8.04M) | ($10.09M) | ($10.74M) | - | ($10.34M) | ($10.92M) | ($10.24M) | - |
| Interest Expense | $407.0K | - | $426.0K | $194.0K | $36.0K | - | $137.0K | $714.0K | $36.0K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($11.82M) | - | ($10.08M) | ($10.56M) | ($11.21M) | - | ($18.84M) | ($7.23M) | ($11.83M) | - |
| EPS - Basic | ($0.65) | - | ($0.60) | ($0.66) | ($0.87) | - | ($1.39) | ($0.64) | ($1.15) | - |
| EPS - Diluted | ($0.65) | - | ($0.60) | ($0.66) | ($0.87) | - | ($1.39) | ($0.64) | ($1.15) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.95M | $18.56M | $20.61M | $22.09M | $18.35M | $17.62M | $26.02M | $3.42M | $11.85M | $12.89M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $272.0K | $672.0K | $321.0K | $3.87M | $4.04M | $1.04M | $1.98M | $1.05M | $1.10M | $4.37M |
| Current Assets | $16.20M | $19.31M | $21.46M | $22.60M | $20.93M | $20.69M | $30.65M | $6.69M | $14.13M | $16.35M |
| Total Assets | $22.69M | $25.86M | $28.28M | $29.53M | $28.14M | $28.18M | $38.39M | $15.75M | $24.48M | $27.15M |
| Current Liabilities | $7.23M | $8.11M | $6.51M | $9.92M | $11.41M | $11.52M | $9.02M | $7.58M | $5.95M | $9.77M |
| Long-term Debt | $9.47M | $9.41M | $9.72M | $20.03M | - | - | - | - | - | - |
| Total Liabilities | $24.13M | $24.23M | $24.47M | $27.69M | $19.24M | $39.49M | $57.37M | $17.40M | $19.61M | $15.77M |
| Stockholders' Equity | ($1.44M) | $1.64M | $3.82M | $1.83M | $8.90M | ($11.31M) | ($18.99M) | ($1.65M) | $4.87M | $11.37M |
| Retained Earnings | ($245.50M) | ($233.67M) | ($225.95M) | ($215.87M) | ($205.31M) | ($194.10M) | ($180.10M) | ($161.26M) | ($154.03M) | ($142.20M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.64M) | - | - | - | ($10.12M) | - | - | - | ($12.12M) | - |
| Investing Cash Flow | - | - | - | - | $0 | - | - | - | $3.0K | - |
| Financing Cash Flow | $8.03M | - | - | - | $10.33M | - | - | - | $11.02M | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($12.12M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.02 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -52.1% | - | -35.6% | -35.8% | -39.8% | - | -49.1% | -45.9% | -48.3% | - |
| Return on equity | 822.8% | - | -264.2% | -575.8% | -125.9% | - | 99.2% | 437.6% | -242.9% | - |
| Return on invested capital | -104.2% | - | -47.0% | -36.5% | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.24 | 2.38 | 3.29 | 2.28 | 1.83 | 1.80 | 3.40 | 0.88 | 2.37 | 1.67 |
| Quick ratio | 2.24 | 2.38 | 3.29 | 2.28 | 1.83 | 1.80 | 3.40 | 0.88 | 2.37 | 1.67 |
| Cash ratio | 2.07 | 2.29 | 3.16 | 2.23 | 1.61 | 1.53 | 2.88 | 0.45 | 1.99 | 1.32 |
| Leverage | ||||||||||
| Debt / Equity | -6.59 | 5.75 | 2.55 | 10.92 | - | - | - | - | - | - |
| Debt / Assets | 0.42 | 0.36 | 0.34 | 0.68 | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -26.0x | - | -18.9x | -52.0x | -298.2x | - | -75.5x | -15.3x | -284.5x | - |
| Equity multiplier | -15.79 | 15.81 | 7.41 | 16.10 | 3.16 | -2.49 | -2.02 | -9.53 | 5.03 | 2.39 |
| Liabilities / Assets | 1.06 | 0.94 | 0.87 | 0.94 | 0.68 | 1.40 | 1.49 | 1.10 | 0.80 | 0.58 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 47.9x | 67.6x | 9.0x | - | - | - | 16.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 1.2% | - | 22.2% | 7.6% | -4.8% | - | 4.0% | -40.5% | -122.3% | - |
| Net income growth (YoY) | -5.5% | - | 46.5% | -46.1% | 5.2% | - | -76.7% | 4.4% | -160.7% | - |
| EPS growth (YoY) | 25.3% | - | 56.8% | -3.1% | 24.3% | - | -9.4% | 73.8% | -666.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | 82.8% | - | - | - | -87.7% | -74.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Elicio Therapeutics against the 5 most active filers in the same SIC group.